London, England, United Kingdom
A dynamic Chairman & Chief Executive with significant board and general management experience of NASDAQ, London Stock Exchange (LSE) publicly quoted and private companies within the biopharmaceutical industry. Focus on creating and realising value for shareholders in short timeframes within limited budgets. Demonstrable success in creating sustainable shareholder value via the execution of corporate strategy allied with strong institutional investor relationships and investor relations strength. Strong experience of corporate turnarounds and optimizing pharmaceutical asset value. Expertise in clinical development, regulatory, commercialization and strategic development. Tremendous success with numerous public & private financings, raising in excess of $400 million, including IPO’s, secondaries and private placements. Expertise in realizing shareholder value via M&A transactions for both private and publicly traded companies. An accomplished leader and team builder, equally adept in strategic and operational execution, having hands-on success in domestic and international markets. A skilled public speaker and active patient advocacy leader.
Ricanto Limited is a next-generation pharmaceutical company focused on unlocking value from underutilised and overlooked therapeutic assets. Our model combines disciplined asset acquisition with advanced AI-driven clinical development and precision commercialisation. We identify high-potential medicines—often approved outside the U.S., discontinued, or underdeveloped—and apply a structured optimisation strategy to accelerate their path to patients and maximise value creation. Ricanto operates through a unique platform approach: • Clinical Development – leveraging AI to redesign development pathways, optimise trial design, and reduce time and cost to approval • Commercial Excellence – deploying digital-first, precision targeting to efficiently reach physicians and patients without legacy infrastructure • Asset-Centric Structure – building dedicated subsidiary companies around each asset to enable strategic flexibility, partnerships, and value realisation at key inflection points Our focus spans high-impact therapeutic areas including neurology, rare disease, cardiometabolic health, and specialty care—where clinical need and commercial opportunity intersect. At Ricanto, we are redefining how pharmaceutical assets are developed, positioned, and monetised—bringing a sharper, faster, and more capital-efficient model to the industry. #Pharma #Biotech #DrugDevelopment #AI #HealthcareInnovation #LifeSciences
Renown Pharma is developing a sub-lingual formulation of apomorphine for the treatment of late-stage Parkinson's disease. Based on a patented dual chamber delivery technology, Renown has already demonstrated sub-lingual concentrations similar to the sub-cutaneous injectable version of apomorphine. The apomorphine is delivered as a pH neutral liquid overcoming the high acidity associated with other forms of apomorphine. renown Pharma is ready to discuss partnering/acquisition of Renown.
Co-founder and former Executive Chairman & CEO.
Achieve is seeking regulatory approval for cytisine, a treatment for smoking cessation. Cytisine has already treated 20 million patients and has 8 million in the safety database. Two Phase 3 clinical trials have been completed in over 2,000 patients and both trials were published in the New England Journal of Medicine, A 740 patient double blind placebo controlled trial (TASC) was conducted by University College London providing evidence that cytisine has similar efficacy but fewer side effects that other prescription smoking cessation aids. A 1,310 patient trial comparing cytisine with nicotine replacement therapy (conducted by the University of Auckland) showed that cytisine was at least as good as NRT in stopping patients smoking. Achieve is developing a patented version of cytisine for the US, EU & Japan and is currently in partnering discussions in developing countries such as India, China, Brazil etc for the currently marketed version.
Brabant Pharma was sold to Zogenix in October 2014. Brabant Pharma is developing a late-stage treatment for Dravet's Syndrome, a catastrophic form of childhood epilepsy. Dravet syndrome (previously known as Severe Myoclonic Epilepsy of Infancy, or SMEI) is a neurodevelopmental disorder beginning in infancy, characterised by intractable seizures. Dravet's is an Orphan disease with fewer than an estimated 30,000 patients worldwide. A major contributor to the cause of Dravet syndrome has been found to be mutations of the SCN1A gene, found in around 80% of patients. This gene contains instructions for the creation of proteins that regulate the function of sodium ion channels. A change (mutation) in this gene may lead to abnormal functioning of the sodium ion channels in the brain, which are presumed to cause seizures. The drug is based on over 20 years of treatment in patients & Brabant is now obtaining regulatory appproval for the drug in EU, US and other major territories